US pharma giant Johnson & Johnson is in talks with the centre to start an early-stage clinical study of its single-dose Covid vaccine in India, the company has said in a statement. The company will soon approach India’s drug regulator for the approval, sources say.
“We are in discussions with the Government of India with the objective of starting a bridging clinical study of our Janssen COVID-19 vaccine candidate in India, subject to local regulatory approvals,” the company said in a statement.
“At Johnson & Johnson, we remain fully focused on bringing a safe and effective COVID-19 vaccine to people around the world, if authorized for use by local health authorities,” it added.